Cargando…

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia

BACKGROUND: Hypoxia is a driving force in pancreatic-ductal-adenocarcinoma (PDAC) growth, metastasis and chemoresistance. The muscle-isoform of lactate dehydrogenase (LDH-A) constitutes a major checkpoint for the switch to anaerobic glycolysis, ensuring supply of energy and anabolites in hypoxic-env...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maftouh, M, Avan, A, Sciarrillo, R, Granchi, C, Leon, L G, Rani, R, Funel, N, Smid, K, Honeywell, R, Boggi, U, Minutolo, F, Peters, G J, Giovannetti, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887288/ https://www.ncbi.nlm.nih.gov/pubmed/24178759 http://dx.doi.org/10.1038/bjc.2013.681

Ejemplares similares

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
por: Massihnia, Daniela, et al.
Publicado: (2017)

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
por: Franczak, Marika A., et al.
Publicado: (2023)

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2020)

Correction: Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2021)

AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients
por: Avan, Abolfazl, et al.
Publicado: (2014)

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
por: Maftouh, Mina, et al.
Publicado: (2014)

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
por: Li Petri, Giovanna, et al.
Publicado: (2020)

Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death
por: Daniele, Simona, et al.
Publicado: (2015)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

Development and Validation of a Docking-Based Virtual Screening Platform for the Identification of New Lactate Dehydrogenase Inhibitors
por: Granchi, Carlotta, et al.
Publicado: (2015)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer
por: Wigfield, S M, et al.
Publicado: (2008)

DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
por: Drouillard, A, et al.
Publicado: (2016)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Effect of peripheral arterial disease on the onset of lactate threshold during cardiopulmonary exercise test: study protocol
por: Key, Angela, et al.
Publicado: (2016)

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
por: van Zweeden, A. A., et al.
Publicado: (2018)

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
por: Bafna, S, et al.
Publicado: (2009)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance
por: Browne, G, et al.
Publicado: (2012)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis
por: Blick, C, et al.
Publicado: (2015)

Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer
por: Shaw, R J, et al.
Publicado: (2009)

Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer
por: Lundgren, K, et al.
Publicado: (2009)

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
por: Jubb, A M, et al.
Publicado: (2009)

Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis
por: Yan, J, et al.
Publicado: (2014)

Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1α is associated with prognosis
por: Rasheed, S, et al.
Publicado: (2009)

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
por: Hussain, S A, et al.
Publicado: (2007)

Protocol for a prospective, controlled, cross-sectional, diagnostic accuracy study to evaluate the specificity and sensitivity of ambulatory monitoring systems in the prompt detection of hypoxia and during movement
por: Areia, Carlos, et al.
Publicado: (2020)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype
por: Barathova, M, et al.
Publicado: (2008)

The effect of hypoxia on the proliferation capacity of dermal papilla cell by regulating lactate dehydrogenase
por: Ye, Jun, et al.
Publicado: (2020)

Hypoxia-induced lactate dehydrogenase A protects cells from apoptosis in endometriosis
por: Zheng, Jinyan, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
por: Mitsunaga, S, et al.
Publicado: (2013)

Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer
por: Angst, E, et al.
Publicado: (2006)

Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence
por: Griffiths, E A, et al.
Publicado: (2007)

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix
por: Kabuubi, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_mrf24hn7e7k0bginf8t60344du